Royalty Pharma (RPRX) Price & Analysis

Compare

1,298 Followers

RPRX Stock Chart & Stats

$45.19

$0.10(0.38%)

At close: Jan 08 4:00 PM EST

$45.19

$0.10(0.38%)

Day’s Range― - ―

52-Week Range$29.66 - $45.91

Previous CloseN/A

Volume726.99K

Average Volume (3M)3.88M

Market Cap

$26.07B

Enterprise Value$18.74B

Total Cash (Recent Filing)$955.04M

Total Debt (Recent Filing)$8.97B

Price to Earnings (P/E)25.4

Beta0.18

Next Earnings

May 07, 2026

EPS Estimate

1.07

Next Dividend Ex-DateN/A

Dividend Yield2.23%

Share Statistics

EPS (TTM)1.47

Shares Outstanding428,418,600

10 Day Avg. Volume4,288,367

30 Day Avg. Volume3,882,144

Financial Highlights & Ratios

PEG Ratio-3.26

Price to Book (P/B)1.71

Price to Sales (P/S)6.98

P/FCF Ratio6.67

Enterprise Value/Market Cap0.72

Enterprise Value/Revenue7.98

Enterprise Value/Gross Profit7.98

Enterprise Value/Ebitda11.84

Forecast

1Y Price Target

$51.43

Price Target Upside13.81% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Dealmaking And Geographic ExpansionA consistent track record of deploying capital into attractive royalties, active dealmaking and plans to increase presence in China raise the likelihood of portfolio additions that enhance long-term growth.

Pipeline Clinical CatalystsPlanned clinical readouts and regulatory decisions for multiple late-stage partnered drugs represent de-risking events that could unlock substantial incremental royalty streams if outcomes are favorable.

Revenue DriversRobust royalty receipts from the cystic fibrosis franchise, Trelegy and Tremfya, together with recent novel launches, strengthen revenue prospects and support higher future royalty income.

Bears Say

Cash Flow And Forecasting UncertaintyUnresolved royalty litigation reduces visibility into future royalty cash flows and complicates forecasting for earnings and distributions.

Investor ConfidenceThe royalty disagreement undermines investor confidence and can pressure the stock's valuation until contractual terms and outcomes are clarified.

Legal And Royalty DisputeAn ongoing royalty dispute represents a material legal overhang that may disrupt expected royalty collections and create execution risk for the company.

Royalty Pharma News

The Week That Was, The Week Ahead: Macro and Markets, Feb. 15

U.S. stocks ended the week lower as investors moved away from big tech and focused more on safer...

1d ago

Royalty Pharma price target raised to $51 from $45 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Royalty Pharma (RPRX) to $51 from $45 and keeps a...

4d ago

RPRX

Royalty Pharma price target raised to $61 from $56 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Royalty Pharma (RPRX) to $61 from $56...

4d ago

RPRX

Royalty Pharma sees FY26 portfolio receipts $3.275B-3.425B

Royalty Pharma’s (RPRX) full year 2026 guidance reflects an estimated foreign exchange impact of approximately +1% to Portfolio...

5d ago

RPRX

Royalty Pharma reports Q4 portfolio receipts of $874M

“We had one of the most remarkable years in Royalty Pharma’s (RPRX) history in 2025,” said Pablo Legorreta,...

5d ago

RPRX

Royalty Pharma upgraded to Buy from Neutral at UBS

UBS analyst Ashwani Verma upgraded Royalty Pharma (RPRX) to Buy from Neutral with a price target of $49,...

17d ago

RPRX

Royalty Pharma price target raised to $50 from $48 at Citi

Citi raised the firm’s price target on Royalty Pharma (RPRX) to $50 from $48 and keeps a Buy...

20d ago

RPRX

Royalty Pharma Earnings Call Balances Strength And Risk

Royalty Pharma PLC (($RPRX)) has held its Q4 earnings call. Read on for the main highlights of the...

2d ago

RPRX

Royalty Pharma PLC (RPRX) Q4 Earnings Cheat Sheet

Royalty Pharma PLC (RPRX) is scheduled to report 4th quarter earnings on 02/11/2026, before the market opens. Regarding...

7d ago

RPRX

Royalty Pharma provides update on business performance

Royalty Pharma (RPRX) provided an update on its business performance, including recent key accomplishments. Key highlights include: Royalty...

1M ago

RPRX

Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408

Royalty Pharma (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced a funding agreement...

1M ago

RPRX

TEVA

Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share

Royalty Pharma (RPRX) announced that its board of directors has declared a dividend for the first quarter of...

1M ago

RPRX

Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront

Royalty Pharma (RPRX) announced that it has acquired the final portion of PTC Therapeutics’ remaining royalty on Roche’s...

2M ago

CHRO

RPRX

Royalty Pharma Announces Planned Legal Leadership Transition

Royalty Pharma ( ($RPRX) ) just unveiled an announcement. On December 20, 2025, Royalty Pharma plc announced that...

2M ago

RPRX

RPRX FAQ

What was Royalty Pharma PLC’s price range in the past 12 months?

Royalty Pharma PLC lowest stock price was $29.66 and its highest was $45.91 in the past 12 months.

What is Royalty Pharma PLC’s market cap?

Royalty Pharma PLC’s market cap is $26.07B.

When is Royalty Pharma PLC’s upcoming earnings report date?

Royalty Pharma PLC’s upcoming earnings report date is May 07, 2026 which is in 80 days.

How were Royalty Pharma PLC’s earnings last quarter?

Royalty Pharma PLC released its earnings results on Feb 11, 2026. The company reported $1.466 earnings per share for the quarter, beating the consensus estimate of $1.286 by $0.18.

Is Royalty Pharma PLC overvalued?

According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Royalty Pharma PLC pay dividends?

Royalty Pharma PLC pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 2.23%. See more information on Royalty Pharma PLC dividends here

What is Royalty Pharma PLC’s EPS estimate?

Royalty Pharma PLC’s EPS estimate is 1.07.

How many shares outstanding does Royalty Pharma PLC have?

Royalty Pharma PLC has 428,418,600 shares outstanding.

What happened to Royalty Pharma PLC’s price movement after its last earnings report?

Royalty Pharma PLC reported an EPS of $1.466 in its last earnings report, beating expectations of $1.286. Following the earnings report the stock price went up 0.09%.

Which hedge fund is a major shareholder of Royalty Pharma PLC?

Currently, no hedge funds are holding shares in RPRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Royalty Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

11.48%

Trailing 12-Months

Asset Growth

7.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Royalty Pharma PLC

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma (RPRX) Earnings & Revenues

Historic Earnings Reports

RPRX Company Deck

RPRX Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call emphasized strong 2025 execution: double-digit growth in royalty and portfolio receipts, attractive returns (ROIC 15.8%, ROIE 22.8%), record synthetic royalty activity, achievement of capital deployment targets ahead of schedule, significant cash generation ($2.7B portfolio cash flow) and meaningful shareholder returns (repurchases and a 7% dividend increase). Offsetting factors include moderated 2026 top-line guidance (royalty growth 3%–8%), a sizable expected drop in milestone receipts (~$68M), higher interest expense in 2026, and execution/timing risk around several pivotal clinical readouts and an ongoing arbitration. Overall, the positives around growth, returns, liquidity, synthetic royalty momentum, and cost savings from internalization outweigh the near-term headwinds and event risks.View all RPRX earnings summaries

RPRX Revenue Breakdown

93.34% Income from financial royalty assets

6.62% Other royalty income

0.04% Revenue from intangible royalty assets

RPRX Stock 12 Month Forecast

Average Price Target

$51.43

▲(13.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","62":"$62","37.25":"$37.3","45.5":"$45.5","53.75":"$53.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,37.25,45.5,53.75,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.36,43.793846153846154,45.22769230769231,46.66153846153846,48.09538461538462,49.52923076923077,50.963076923076926,52.39692307692307,53.830769230769235,55.26461538461538,56.698461538461544,58.13230769230769,59.566153846153846,{"y":61,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.36,43.05769230769231,43.755384615384614,44.45307692307692,45.15076923076923,45.848461538461535,46.54615384615384,47.24384615384615,47.941538461538464,48.63923076923077,49.33692307692308,50.034615384615385,50.73230769230769,{"y":51.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.36,42.56307692307692,42.76615384615385,42.96923076923077,43.17230769230769,43.37538461538462,43.57846153846154,43.78153846153846,43.98461538461538,44.18769230769231,44.39076923076923,44.59384615384615,44.79692307692308,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.803,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.031,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.605,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.892,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.876,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.466,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.682,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.78,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.118,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.332,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >